IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer

References

• Lynch CF, Cohen MB. Urinary system. Cancer 1995;75(1 Suppl):316-29; PMID:8001003; http://dx.doi.org/10.1002/1097-0142(19950101)75:1+%3c316::AID-CNCR2820751314%3e3.0.CO;2-T
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166(5):1611-23; PMID:11586189; http://dx.doi.org/10.1016/S0022-5347(05)65640-6
   PubMed Web of Science ®Google Scholar
• Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281(17):1628-31; PMID:10235157; http://dx.doi.org/10.1001/jama.281.17.1628
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108; PMID:15761078; http://dx.doi.org/10.3322/canjclin.55.2.74
   PubMed Web of Science ®Google Scholar
• Murai M, Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol 2004;14(4):229-33; PMID:15205579; http://dx.doi.org/10.1097/01.mou.0000135078.04721.f5
   PubMed Web of Science ®Google Scholar
• Marugame T, Matsuda T. Comparison of time trends in kidney cancer incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents, Vols IV-VIII. Jpn J Clin Oncol 2008;38(7):508-9; PMID:18664483; http://dx.doi.org/10.1093/jjco/hyn060
   PubMedGoogle Scholar
• Vaishampayan UN, Do H, Hussain M, Schwartz K. Racial disparity in incidence patterns and outcome of kidney cancer. Urology 2003;62(6):1012-7; PMID:14665346; http://dx.doi.org/10.1016/j.urology.2003.07.010
   PubMed Web of Science ®Google Scholar
• Horner MJ, Ries LAG, Krapcho M et al. SEER Cancer Statistics Review, 1975-2006. based on November 2008 SEER data submission. 2009. http://seer.cancer.gov/csr/1975_2006/, National Cancer Institute. Bethesda, MD.
   Google Scholar
• Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006;176(6 Pt 1):2353-8; PMID:17085101; http://dx.doi.org/10.1016/j.juro.2006.07.130
   PubMed Web of Science ®Google Scholar
• Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol 2008;782381; PMID:19009036
   PubMedGoogle Scholar
• Nepple KG, Yang L, Grubb RL, III, Strope SA. Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006. J Urol 2012;187(1):32-38; PMID:22088338; http://dx.doi.org/10.1016/j.juro.2011.09.028
   PubMed Web of Science ®Google Scholar
• Nepple, Wood. Kidney cancer on the rise. 2011. Genitourinary Cancers Symposium, Orlando, Fla., Feb. Seventeen-19, 2011.
   Google Scholar
• Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P, La Vecchia C. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008;101(8):949-58; PMID:18241251; http://dx.doi.org/10.1111/j.1464-410X.2008.07451.x
   PubMed Web of Science ®Google Scholar
• Mathew A, Devesa SS, Fraumeni JF, Jr., Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 2002;11(2):171-8; PMID:11984136; http://dx.doi.org/10.1097/00008469-200204000-00010
   PubMed Web of Science ®Google Scholar
• Tate R, Iddenden R, Harnden P et al. Increased incidence of renal parenchymal carcinoma in the Northern and Yorkshire region of England, 1978-1997. Eur J Cancer 2003;39(7):961-7; PMID:12706365; http://dx.doi.org/10.1016/S0959-8049(03)00070-4
   PubMed Web of Science ®Google Scholar
• Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008;14(5):288-301; PMID:18836333; http://dx.doi.org/10.1097/PPO.0b013e3181867628
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46(4):765-781; PMID:20116997; http://dx.doi.org/10.1016/j.ejca.2009.12.014
   PubMed Web of Science ®Google Scholar
• Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, Dalrymple NC, Chintapalli KN. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006;26(6):1795-1806; PMID:17102051; http://dx.doi.org/10.1148/rg.266065010
   PubMed Web of Science ®Google Scholar
• Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009;40(1):10-29; PMID:19027455; http://dx.doi.org/10.1016/j.humpath.2008.09.009
   PubMed Web of Science ®Google Scholar
• Algaba F, Trias I, Scarpelli M, Boccon-Gibod L, Kirkali Z, van PH. Handling and pathology reporting of renal tumor specimens. Eur Urol 2004;45(4):437-443; PMID:15041106; http://dx.doi.org/10.1016/j.eururo.2003.11.026
   PubMed Web of Science ®Google Scholar
• Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27(5):612-624; PMID:12717246; http://dx.doi.org/10.1097/00000478-200305000-00005
   PubMed Web of Science ®Google Scholar
• Jones TD, Eble JN, Cheng L. Application of molecular diagnostic techniques to renal epithelial neoplasms. Clin Lab Med 2005; 25(2):279-303; PMID:15848737; http://dx.doi.org/10.1016/j.cll.2005.01.011
   PubMed Web of Science ®Google Scholar
• Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC, Press, Lyon. In press.
   Google Scholar
• Staehler M, Rohrmann K, Bachmann A, Zaak D, Stief CG, Siebels M. Therapeutic approaches in metastatic renal cell carcinoma. BJU Int 2005;95(8):1153-61; PMID:15877725; http://dx.doi.org/10.1111/j.1464-410X.2005.05537.x
   PubMed Web of Science ®Google Scholar
• Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, Schmidinger M. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 2006; 95(6):691-8; PMID:16940978; http://dx.doi.org/10.1038/sj.bjc.6603327
   PubMed Web of Science ®Google Scholar
• Ljungberg B. The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. Curr Urol Rep 2013;14(1):19-25; PMID:23212738; http://dx.doi.org/10.1007/s11934-012-0293-6
   PubMed Web of Science ®Google Scholar
• Stadler WM. Maturing of renal cancer therapeutics. J Clin Oncol 2014;32(8):722-724; PMID:24516015; http://dx.doi.org/10.1200/JCO.2013.54.1748
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009;7(6):618-30; PMID:19555584
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC; European Association of Urology Guideline Group. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. Eur Urol 2010;58:398-406; PMID:20633979
   PubMed Web of Science ®Google Scholar
• Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v137-9; PMID:20555064; http://dx.doi.org/10.1093/annonc/mdq206
   PubMed Web of Science ®Google Scholar
• Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11:213-44; PMID:8476560; http://dx.doi.org/10.1146/annurev.iy.11.040193.001241
   PubMed Web of Science ®Google Scholar
• Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, Meijer S, Vos W, Wijnands PG, Scheper RJ, de Gruijl TD. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol 2005;167(5):1301-7; PMID:16251414; http://dx.doi.org/10.1016/S0002-9440(10)61217-5
   PubMed Web of Science ®Google Scholar
• Weinschenk T, Singh H, Mahr A, Fritsche J. Biomarkers for predicting the efficacy of an immunotherapy against cancer, Patent PCT/EP2011/070661, published as WO2012069462. 2012 May 31.
   Google Scholar
• Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012;135(Pt 4):1042-54; PMID:22418738; http://dx.doi.org/10.1093/brain/aws042
   PubMed Web of Science ®Google Scholar
• Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine 2007;25 Suppl 2:B72-88; PMID:17916464; http://dx.doi.org/10.1016/j.vaccine.2007.06.043
   PubMed Web of Science ®Google Scholar
• Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006;25(5-6):321-352; PMID:17169779; http://dx.doi.org/10.1080/08830180600992498
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Biskamp M, Jaeger E, Karbach J et al. Phase I study of intensive course immunization with NY-ESO-1 peptides in HLA-A2+ patients with NY-ESO-1+ cancer. ASCO Conference 2003. Proc Am Soc Clin Oncol (ASCO 2003) 22[706].2003
   Google Scholar
• Gaudernack G, Buanes T, Meo M et al. Clinical trials of a peptide based vaccine targeting telomerase. Proc Am Soc Clin Oncol (ASCO 2003) 22[666].2003.
   Google Scholar
• Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18(2):226-32; PMID:17116643; http://dx.doi.org/10.1093/annonc/mdl158
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
   PubMed Web of Science ®Google Scholar
• Chen W, Cai MY, Wei DP, Wang X. Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma. World J Gastroenterol 2005;11(21):3297-9; PMID:15929187
   PubMed Web of Science ®Google Scholar
• Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200(6):771-82; PMID:15381730; http://dx.doi.org/10.1084/jem.20041130
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC, Jr., Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984;44(11):5439-5443; PMID:6488195
   PubMed Web of Science ®Google Scholar
• Faries MB, Hsueh EC, Gupta RK et al. Immunomodulation of responses to active immunization with a polyvalent immunotherapeutic: cyclophosphamide, H2 blockade, IL-2/IFNa and GM-CSF. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Vol 23, No.16S, Part I of II (June 1 Supplement)[2564].2005.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, , Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641-8; PMID:16960692; http://dx.doi.org/10.1007/s00262-006-0225-8
   PubMed Web of Science ®Google Scholar
• Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, Manns MP, Korangy F. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010;33(2):211-8; PMID:20139774; http://dx.doi.org/10.1097/CJI.0b013e3181bb499f
   PubMed Web of Science ®Google Scholar
• Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14(5):1455-63; PMID:18316569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0371
   PubMed Web of Science ®Google Scholar
• Livingston PO, Cunningham-Rundles S, Marfleet G, Gnecco C, Wong GY, Schiffman G, Enker WE, Hoffman MK, et al. Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod 1987;6(4):392-403; PMID:2957470
   PubMedGoogle Scholar
• Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48(20):5883-93; PMID:3262416
   PubMed Web of Science ®Google Scholar
• Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, Gillanders WE, Cole DJ. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 2007;30(1):40-53; PMID:17198082; http://dx.doi.org/10.1097/01.cji.0000211311.28739.e3
   PubMed Web of Science ®Google Scholar
• Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, Luznik L. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother 2010;59(1):137-48; PMID:19590872; http://dx.doi.org/10.1007/s00262-009-0734-3
   PubMed Web of Science ®Google Scholar
• Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010;115(22):4384-92; PMID:20154220; http://dx.doi.org/10.1182/blood-2009-11-251231
   PubMed Web of Science ®Google Scholar
• Liu Y, Laszlo C, Liu Y, Liu W, Chen X, Evans SC, Wu S. Regulation of G(1) arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2alpha phosphorylation. Neoplasia 2010;12(1):61-68; PMID:20072654
   PubMed Web of Science ®Google Scholar
• Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001;194(11):1549-59; PMID:11733570; http://dx.doi.org/10.1084/jem.194.11.1549
   PubMed Web of Science ®Google Scholar
• Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza JL. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 2001;166(11):6608-15; PMID:11359814; http://dx.doi.org/10.4049/jimmunol.166.11.6608
   PubMed Web of Science ®Google Scholar
• Fuentes D, Avellanet J, Garcia A, Iglesias N, Gabri MR, Alonso DF, Vazquez AM, Perez R, Montero E. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat 2010;120(2):379-389; PMID:19377876; http://dx.doi.org/10.1007/s10549-009-0399-9
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/92.3.205
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. 2011.
   Google Scholar
• Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol 2012;23 Suppl 8:viii47-52; PMID:22918928; http://dx.doi.org/10.1093/annonc/mds263
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-79; PMID:19536890; http://dx.doi.org/10.1002/cncr.24429
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-94; PMID:16809734; http://dx.doi.org/10.1200/JCO.2005.04.5252
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68; PMID:24331154; http://dx.doi.org/10.1016/S1470-2045(13)70510-2
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(7):1099-105; PMID:20100959; http://dx.doi.org/10.1200/JCO.2009.25.0597
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, Strigård K, Eriksson E, Samanci A, Choudhury A, Nilsson B, Rossmann ED, Mosolits S, et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004;10(10):3273-81; PMID:15161680; http://dx.doi.org/10.1158/1078-0432.CCR-03-0706
   PubMed Web of Science ®Google Scholar
• Staff C, Magnusson CG, Hojjat-Farsangi M, Mosolits S, Liljefors M, Frödin JE, Wahrén B, Mellstedt H, Ullenhag GJ. Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol 2012;32:855-65; PMID:22382876
   PubMed Web of Science ®Google Scholar
• Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005;16(6):847-62; PMID:15829493; http://dx.doi.org/10.1093/annonc/mdi192
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64(14):4973-79; PMID:15256471; http://dx.doi.org/10.1158/0008-5472.CAN-03-3505
   PubMed Web of Science ®Google Scholar
• Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dörfel D, Schmidt SM, Häntschel M, Brugger W, Schröder S, Horger MS, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66(11):5910-18; PMID:16740731; http://dx.doi.org/10.1158/0008-5472.CAN-05-3905
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18; PMID:19451442; http://dx.doi.org/10.1200/JCO.2008.19.5511
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24; PMID:16330672; http://dx.doi.org/10.1200/JCO.2005.02.2574
   PubMed Web of Science ®Google Scholar
• Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174(10):5994-6004; PMID:15879092; http://dx.doi.org/10.4049/jimmunol.174.10.5994
   PubMed Web of Science ®Google Scholar
• Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 2014; 74:2974-85; PMID:24728077; http://dx.doi.org/10.1158/0008-5472.CAN-13-2564
   PubMed Web of Science ®Google Scholar
• Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical evidence that PD-1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014;74:4042-52; PMID:24812273; http://dx.doi.org/10.1158/0008-5472
   PubMed Web of Science ®Google Scholar
• Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41(10):2977-86; PMID:21710477; http://dx.doi.org/10.1002/eji.201141639
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13(5):501-8; PMID:22326924; http://dx.doi.org/10.1016/S1470-2045(12)70006-2
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013;36(7):382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2
   PubMed Web of Science ®Google Scholar
• Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009;15(19):6267-76; PMID:19789309; http://dx.doi.org/10.1158/1078-0432.CCR-09-1254
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Cho D, Sosman JA, Sznol M et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31[(15_suppl), Abstract 4505]. 2013.
   Web of Science ®Google Scholar